Millennium Pharmaceuticals, Inc. (South San Francisco, California)

100 articles with Millennium Pharmaceuticals, Inc. (South San Francisco, California)

• 

  Deborah Dunsire Takes Over as CEO of Denmark’s H. Lundbeck

  7/2/2018

  Former XTuit Pharmaceuticals Chief Executive Officer Deborah Dunsire has been appointed head of Denmark-based H. Lundbeck A/S.

• The BIO International Convention Begins Day Three with Keynote Speech from Actor, Director and Advocate Rob Reiner

  6/6/2018

  Wednesday programming will emphasize the patient and the role of the biotech industry in delivering care.

• 

  CEOs, Directors and Other Senior Executives Tapped by Biotech

  5/21/2018

  Pharma and biotech companies across the globe continued to expand and reshape their leadership teams with new hires this past week. BioSpace collected several announced leadership appointments, which includes new chief executive officers, new members to boards of directors and more.
• 

  Casma Therapeutics Launches with $58.5 Million

  5/3/2018

  Casma Therapeutics closed on a Series A round totaling $58.5 million. The company was solely funded by Third Rock Ventures.

• SEC Sues Filmmaker for Insider Trading Ahead of Millennium Pharmaceuticals, Inc. (South San Francisco, California), Sepracor Acquisitions

  9/24/2013

• Millennium Pharmaceuticals, Inc. (South San Francisco, California) Announces $13 Million Equity Financing

  6/13/2011

• Millennium Pharmaceuticals, Inc. (South San Francisco, California) VELCADE Improved Outcomes in Multiple Myeloma Patients After Transplant in Nordic Myeloma Study

  5/6/2011

• Millennium Pharmaceuticals, Inc. (South San Francisco, California) Leadership in Proteasome Inhibition Highlighted in Relapsed/Refractory Multiple Myeloma At IMW Meeting

  5/5/2011

• Millennium Pharmaceuticals, Inc. (South San Francisco, California) Submits Two Supplemental NDAs to FDA for VELCADE

  4/26/2011

• Millennium Pharmaceuticals, Inc. (South San Francisco, California) and Sunesis Pharmaceuticals, Inc. Announce Collaboration for Kinase Inhibitors in Oncology; Sunesis Receives a $4 Million Payment

  4/5/2011

• Millennium Pharmaceuticals, Inc. (South San Francisco, California) Becomes First Licensed Customer for BioClinica, Inc.’s New Enterprise Demand Aggregator

  3/30/2011

• Millennium Pharmaceuticals, Inc. (South San Francisco, California) Selects OrgPlus to Deliver Accurate Workforce Insight

  7/13/2010

• Seattle Genetics, Inc. and Millennium Pharmaceuticals, Inc. (South San Francisco, California) Announce Initiation of Phase I Combination Clinical Trial of Brentuximab Vedotin (SGN-35) for Front-line Hodgkin Lymphoma

  2/3/2010

• Seattle Genetics, Inc. Announces Antibody-Drug Conjugate Collaboration With Millennium: The Takeda Oncology Company

  4/6/2009

• Millennium Pharmaceuticals, Inc. (South San Francisco, California) New Data Will Be Presented at ASH on VELCADE(R) (Bortezomib) for Injection-Based Therapies in Multiple Myeloma and Non-Hodgkin's Lymphoma

  11/18/2008

• Horizon Discovery Announces Commercial Agreement with Millennium Pharmaceuticals, Inc. (Cambridge, Massachusetts)

  9/17/2008

• Small is Beautiful -- BioPharm Executive

  6/25/2008

• Millennium Pharmaceuticals, Inc. (Cambridge, Massachusetts) Cancer Drug Velcade Might Work in Lupus According to Study

  6/9/2008

• Takeda Pharmaceutical Co. Ltd. Successfully Completes Tender Offer for Millennium Pharmaceuticals, Inc. (Cambridge, Massachusetts) and Announces Subsequent Offering Period

  5/9/2008

• Biotech Blossoms Anew

  4/30/2008